Analysis: Ceramide Skincare from Birth May Mitigate Pediatric AD

Key Takeaways

• A new study shows a modified Delphi panel defined SAIGE factors and their impact on pediatric atopic dermatitis (AD) development.

• Continuous ceramide-based skincare from birth may delay or reduce disease severity.

• Researchers said clinician education is vital for early recognition and mitigation of modifiable risk factors.

A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).

Publishing the paper in the Journal of Drugs in Dermatology, the authors developed by a global panel of seven dermatology experts using a modified Delphi process, the guidance aims to support clinicians in mitigating disease progression from birth. The panel reviewed existing literature to develop five consensus statements. These recommendations identify SAIGE factors as central contributors to skin barrier disruption and AD onset. The panel emphasized the importance of reducing modifiable exposures to delay the onset and lessen the severity of AD.

According to the paper, continuous skincare initiated from birth, particularly in high-risk populations, was noted as preventive approach. Ceramide-containing emollients were recommended based on their role in reinforcing barrier function and delaying flares. The panel also called for increased education for clinicians regarding the role of SAIGE factors in pediatric AD pathogenesis. 

"Recognizing and mitigating SAIGE factors and initiating ceramide-containing skincare from birth are important," the authors concluded. "Clinician education is needed to improve understanding of the impact of SAIGE factors and therapeutic strategies that may delay flares and reduce severity."

Source: Schachner L, et al. Journal of Drugs in Dermatology. 2025;24(10):1012.